Barchelouei Niloofar Khosrobaki, Yazdi Mohammad Hossein, Haghighat Setareh
Department of Microbiology, TeMS.C., TeMS.C, Islamic Azad University, Tehran, Iran.
Biotechnology Research Center, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mol Biol Rep. 2025 Aug 8;52(1):809. doi: 10.1007/s11033-025-10873-w.
Breast cancer is a prevalent malignancy in women worldwide, with recurrence and treatment-related side effects posing significant challenges. Immunotherapy has shown promise, yet an immunosuppressive tumor microenvironment can hinder its effectiveness. Emerging evidence suggests that probiotics, particularly Lactobacillus species, may positively influence immune responses and tumor progression in the context of cancer therapy.
This study evaluated the effects of Lactobacillus reuteri PTCC1058 on tumor development and immune responses in a mouse model of breast cancer induced by 4T1 mouse breast carcinoma cells. Female BALB/c mice were divided into probiotic and control groups, receiving oral supplementation of the probiotic or PBS, respectively, for 30 days before and after tumor induction. Tumor volume and survival were assessed over 70 days. The expression levels of key immune mediators, tumor Necrosis Factor alpha (TNF alpha), Interleukin 10 (IL-10), transforming growth factor beta (TGF-β), Indoleamine 2,3-dioxygenase (IDO), and Fas ligand (FasL) were measured using quantitative real-time PCR, and histopathological analysis was conducted on tumor tissues.
Probiotic treatment exhibited a trend towards reduced tumor volume and improved survival, although not statistically significant (p > 0.05). Key immune mediators showed significant changes, with TGF-β, IL-10, and IDO expressions downregulated and TNF-α and FasL upregulated in the probiotic group (P < 0.01). Histopathological analysis revealed reduced pleomorphism, mitotic activity, and focal necrosis in the probiotic group.
The findings indicate that L. reuteri PTCC1058 may modulate the tumor microenvironment and influence immune responses in breast cancer. While further research is necessary to validate these results, probiotics could represent a complementary therapeutic strategy in breast cancer treatment.
乳腺癌是全球女性中普遍存在的恶性肿瘤,复发和治疗相关的副作用带来了重大挑战。免疫疗法已显示出前景,但免疫抑制性肿瘤微环境可能会阻碍其有效性。新出现的证据表明,益生菌,特别是乳酸杆菌属,在癌症治疗背景下可能对免疫反应和肿瘤进展产生积极影响。
本研究评估了罗伊氏乳杆菌PTCC1058对4T1小鼠乳腺癌细胞诱导的乳腺癌小鼠模型中肿瘤发展和免疫反应的影响。雌性BALB/c小鼠分为益生菌组和对照组,在肿瘤诱导前后分别口服补充益生菌或磷酸盐缓冲盐水(PBS),持续30天。在70天内评估肿瘤体积和存活率。使用定量实时聚合酶链反应(PCR)测量关键免疫介质肿瘤坏死因子α(TNFα)、白细胞介素10(IL-10)、转化生长因子β(TGF-β)、吲哚胺2,3-双加氧酶(IDO)和Fas配体(FasL)的表达水平,并对肿瘤组织进行组织病理学分析。
益生菌治疗呈现出肿瘤体积减小和存活率提高的趋势,尽管无统计学意义(p>0.05)。关键免疫介质有显著变化,益生菌组中TGF-β、IL-10和IDO的表达下调,TNF-α和FasL上调(P<0.01)。组织病理学分析显示益生菌组的多形性、有丝分裂活性和局灶性坏死减少。
研究结果表明,罗伊氏乳杆菌PTCC1058可能调节肿瘤微环境并影响乳腺癌中的免疫反应。虽然需要进一步研究来验证这些结果,但益生菌可能代表乳腺癌治疗中的一种辅助治疗策略。